Pharmaceutical Executive Daily: FDA Shelves CNPV Program

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, the FDA reportedly shelves its Commissioner’s National Priority Voucher program for expedited drug reviews, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site to produce next-generation obesity treatments like retatrutide, and Parexel chief patient officer Stacy Hurt on why small protocol decisions can become major barriers to trial enrollment and retention.

FDA has shelved its Commissioner’s National Priority Voucher program, according to six sources familiar with the matter, with the political appointee executive council that drove expedited reviews reportedly gone dormant. No new vouchers have been awarded since former commissioner Marty Makary left the agency in May.

Eli Lilly broke ground on a $3.5 billion manufacturing facility in Pennsylvania’s Lehigh Valley, part of the company’s broader $50 billion U.S. manufacturing push. The site will add injectable capacity for next-generation obesity treatments including retatrutide, is expected to be operational by 2031, and will create 850 permanent jobs along with roughly 2,000 construction jobs.

Finally, Parexel chief patient officer Stacy Hurt argues that every protocol decision carries real weight for patients, and that only those with lived disease experience can accurately identify which requirements, from invasive biopsies to daily trial demands, create true burden. She makes the case that sponsors who overlook these seemingly small decisions risk undermining enrollment and retention later in the trial.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.